GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (NAS:IMUX) » Definitions » Shiller PE Ratio

Immunic (Immunic) Shiller PE Ratio : (As of May. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Immunic Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Immunic Shiller PE Ratio Historical Data

The historical data trend for Immunic's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Shiller PE Ratio Chart

Immunic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immunic Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunic's Shiller PE Ratio

For the Biotechnology subindustry, Immunic's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunic's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Immunic's Shiller PE Ratio falls into.



Immunic Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Immunic's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Immunic's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.3/131.7762*131.7762
=-0.300

Current CPI (Mar. 2024) = 131.7762.

Immunic Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -36.400 100.560 -47.700
201409 -23.600 100.428 -30.967
201412 -23.600 99.070 -31.391
201503 -24.800 99.621 -32.805
201506 -25.200 100.684 -32.982
201509 -20.400 100.392 -26.778
201512 -13.600 99.792 -17.959
201603 -12.400 100.470 -16.264
201606 -12.000 101.688 -15.551
201609 -12.800 101.861 -16.559
201612 -14.800 101.863 -19.146
201703 -15.600 102.862 -19.985
201706 -11.600 103.349 -14.791
201709 -12.000 104.136 -15.185
201712 -14.000 104.011 -17.737
201803 -13.600 105.290 -17.021
201806 -12.000 106.317 -14.874
201809 -11.200 106.507 -13.857
201812 -2.400 105.998 -2.984
201903 -5.090 107.251 -6.254
201906 -1.520 108.070 -1.853
201909 -0.820 108.329 -0.997
201912 -0.560 108.420 -0.681
202003 -0.790 108.902 -0.956
202006 -0.900 108.767 -1.090
202009 -0.700 109.815 -0.840
202012 -0.460 109.897 -0.552
202103 -1.630 111.754 -1.922
202106 -0.820 114.631 -0.943
202109 -0.760 115.734 -0.865
202112 -0.600 117.630 -0.672
202203 -0.740 121.301 -0.804
202206 -0.720 125.017 -0.759
202209 -0.690 125.227 -0.726
202212 -1.620 125.222 -1.705
202303 -0.580 127.348 -0.600
202306 -0.540 128.729 -0.553
202309 -0.510 129.860 -0.518
202312 -0.480 129.419 -0.489
202403 -0.300 131.776 -0.300

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Immunic  (NAS:IMUX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Immunic Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Immunic's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunic (Immunic) Business Description

Traded in Other Exchanges
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Executives
Glenn Whaley officer: PAO and Controller C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Richard Alan Rudick director 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK NY 10036
Joerg Neermann director IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Daniel Vitt director, officer: CEO, President IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Monika Maria Toernsen director ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Duane Nash director C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andreas Muehler officer: Chief Medical Officer 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY NY 10036
Manfred Groeppel officer: Chief Operating Officer IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Barclay A Phillips director C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Tamar D Howson director
Sanjay S Patel officer: Chief Financial Officer 10 N. PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Claudio Nessi 10 percent owner C/O NEOMED, 7 PLACE DU MOLARD, 1204 GENEVA V8 1204
Anne-mari Paster 10 percent owner C/O OMEGA FUND MANAGEMENT, LLC, 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Lsp V Cooperatieve U.a. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV